Renal cell carcinoma or kidney cancer drugs are often used as the first line of treatment against advanced kidney cancers. They can often shrink or slow the growth of the cancer for a time, but it doesn’t seem that any of these drugs can actually cure kidney cancer. Kidneys serve as natural blood filters, removing the water soluble wastes and reabsorbing the essential elements from the blood. Since they play such a crucial role, kidneys require constant regeneration of dead nephrons and proper blood circulation to maintain healthy cell growth, due to which, they are susceptible to metastasis and cancerous tumors. Renal cell carcinoma, the most common type of kidney cancer, is among the toughest cancers to treat, especially in the advanced stages. Several targeted drugs can be used to treat advanced kidney cancer. These drugs block angiogenesis (growth of the new blood vessels that nourish cancers) or important proteins in cancer cells (called tyrosine kinases) that help them grow and survive.
The global kidney cancer drugs market report estimates the market size (Revenue US$ million – 2014 to 2021) for key market segments based on the drug type (brand) such as Afinitor (everolimus), Avastin (bevacizumab), Inlyta (axitinib), Nexavar (sorafenib), Proleukin (aldesleukin), Sutent (sunitinib), Torisel (temsirolimus), Votrient (pazopanib), clinical phase 1, 2 and 3 drugs (AGS-003, Cabozantinib, Dovitinib, Keytruda, Opdivo) pipeline analysis, and forecasts growth trends (CAGR% – 2017 to 2021).
The global kidney cancer drugs market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global kidney cancer drugs market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.
Major players operating in the global kidney cancer drugs market and included in this report are Novartis AG., F. Hoffman-La Roche., Pfizer, Inc., Bayer Pharma AG., and GlaxoSmithKline, plc.